Table 4. Results of Cox regression analysis of significant independent clinicopathological actors and high tumour stromal expression of mir-21 versus BF and CF.
Biochemical Failure (BF) | Clinical Failure (CF) | ||||
Variable | HR (95% CI) | p | HR (95% CI) | p | |
pT-Stage | pT2 | 1 | <0.001 | Not Significant | |
pT3a | 1.7 (1.1–2.5) | 0.011 | |||
pT3b | 2.6 (1.6–4.2) | <0.001 | |||
Preop PSA | 1.4 (1.0–1.9) | 0.069 | Not Significant | ||
Gleason | 3+3 | 1 | 0.021 | 1 | 0.013 |
3+4 | 1.0 (0.7–1.5) | 0.999 | 2.7 (0.9–8.6) | 0.085 | |
4+3 | 1.5 (0.9–2.4) | 0.125 | 3.5 (1.0–12.1) | 0.047 | |
8–10 | 1.9 (1.3–2.7) | 0.008 | 6.6 (2.1–21.2) | 0.002 | |
Perineural infiltration | Not Significant | 2.3 (1.1–4.7) | 0.031 | ||
Vascular infiltration | Not Significant | Not Significant | |||
Apical PSM | 0.6 (0.4–0.8) | 0.003 | Not Significant | ||
Non-apical PSM | 1.9 (1.3–2.7) | <0.001 | 2.9 (1.4–6.1) | 0.004 | |
hsa -miR-21 | 1.4 (1.0–1.9) | 0.089 | Not Significant |